Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
12.78
-6.83 (-34.83%)
At close: Apr 25, 2025, 4:00 PM
13.00
+0.22 (1.72%)
After-hours: Apr 25, 2025, 6:19 PM EDT
Company Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.
Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer.
The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors, such as soft tissue sarcomas and thymic cancer.
Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Instil Bio, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Mar 19, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Bronson Crouch |
Contact Details
Address: 3963 Maple Avenue, Suite 350 Dallas, Texas 75219 United States | |
| Phone | 972 499 3350 |
| Website | instilbio.com |
Stock Details
| Ticker Symbol | TIL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001789769 |
| CUSIP Number | 45783C101 |
| ISIN Number | US45783C2008 |
| Employer ID | 83-2072195 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bronson Crouch | Chairman and Chief Executive Officer |
| Dr. Sandeep Laumas M.D. | Chief Financial Officer and Chief Business Officer |
| Dr. Andres A. Gutierrez M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2025 | ARS | Filing |
| Apr 14, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 14, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 31, 2025 | 424B5 | Filing |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 4, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 4, 2025 | 10-K | Annual Report |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Jan 14, 2025 | 8-K | Current Report |